Related Experiment Videos
Drug-induced pancreatitis: An update.
Jie Zheng1, Qiu-Jin Yang1, Fu-Tao Dang1
1Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.
Summary
Drug-induced pancreatitis, though rare, is increasing with widespread drug use. Advances in understanding its causes, diagnosis, and prevention, including pharmacogenomics, are crucial.
Area of Science:
- Gastroenterology and Hepatology
- Clinical Pharmacology
Background:
- Drug-induced pancreatitis (DIP) is a significant clinical concern with increasing incidence.
- Current epidemiological data, particularly from China, are limited.
- Understanding DIP's risk factors, pathogenesis, and diagnostic challenges is critical.
Purpose of the Study:
- To comprehensively review recent advances in drug-induced pancreatitis.
- To highlight progress in incidence, risk factors, pathogenesis, diagnosis, treatment, and prevention.
- To explore the potential of pharmacogenomics in managing DIP.
Main Methods:
- Systematic literature review focusing on drug-induced pancreatitis over the last 10 years.
- Analysis of epidemiological trends, etiological factors, and diagnostic methodologies.
- Evaluation of emerging treatment and prevention strategies, including pharmacogenomics.
Main Results:
- DIP incidence is low but rising globally, with regional variations noted.
- Progress in understanding DIP pathogenesis requires further investigation.
- A new diagnostic approach is emerging, moving beyond diagnosis of exclusion.
- Pharmacogenomics shows promise for personalized prevention and treatment.
Conclusions:
- Drug-induced pancreatitis is an evolving clinical challenge requiring ongoing research.
- Enhanced diagnostic strategies and pharmacogenomic applications are key to future management.
- Further epidemiological studies, especially in underrepresented regions, are needed.